http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Neuropsychological and psychosocial foundations of neuro-oncology
Neuropsychological & Psychosocial Foundations of Neuro-Oncology provides an in-depth review of common cognitive, psychological, and social manifestations that occur in patients with brain cancer and other neuro-oncological issues, Chapters discuss primary CNS tumors, brain metastases, leptomeningeal disease, paraneoplastic disorders, and many.
Intro -- Neuropsychological and Psychosocial Foundations of Neuro-Oncology -- Copyright -- Dedication -- Contents -- Contributors -- About the editors -- Preface -- Section I: Neuropsychological foundations of neuro-oncology -- Chapter 1: History of neuro-oncology and neuropsychology -- Introduction -- History of neuro-oncology -- History of neuropsychology -- References -- Chapter 2: Neurocognitive functioning: From brain structures to networks -- Introduction -- Short historical background -- Neurocognitive domains -- Primary functions: Visual, auditory perception, and sensorimotor function -- Higher order neurocognitive functions -- Information processing speed -- Attention -- Memory -- Executive functioning -- Motor and action -- Social cognition -- Language -- A network approach -- Short historical background and introduction into network theory -- Network neuroscience -- Measuring networks in humans -- Individual differences and variability -- Conclusion -- References -- Chapter 3: Taking a therapeutic and biopsychosocial approach to the neuropsychological interview for assessment of brain ... -- Introduction -- Assessment models in neuropsychology -- Informed consent as an ongoing process -- Biopsychosocial model in the neuropsychological assessment of primary brain tumor patients -- Assessment domains -- Cognitive symptoms -- Psychosocial distress: Mood, anxiety, trauma -- Sleep and fatigue -- Social functioning and support -- Identity changes -- Work and disability -- Sexual health and intimacy -- Caregiver burden -- Final thoughts -- References -- Chapter 4: Neuropsychological assessment in neuro-oncology -- Introduction -- Foundations of objective neuropsychological assessment -- Neuropsychological assessment in neuro-oncology -- Prerequisites to neuropsychological assessment -- Neurocognitive domains and the tests that measure them.
Interpretation of neuropsychological findings -- Guidlines for objective neuropsychological assessment in neuro-oncology -- Objective neuropsychological assessment in clinical trials -- Future directions -- Conclusions -- References -- Chapter 5: Patient-reported assessment: Identifying cognitive concerns in brain tumor patients -- Definitions and incidence -- Subjective cognitive function -- Clinical practice implementation -- Subjective cognitive function measurement -- Instruments for initial screening -- Subjective cognitive function instruments -- Association with objective neuropsychological assessments -- Implications for practice -- References -- Chapter 6: Quality of life and patient-reported outcomes in neuro-oncology clinical care and research -- Introduction -- Quality of life in neuro-oncology -- Determinants of QoL -- Tumor and treatment-related factors -- Symptom burden and functional limitations -- Socioeconomic factors -- Social support -- Quality of life measurement approaches -- Multidimensional PROMs -- EORTC QLQ-C30 -- EORTC QLQ-BN20 -- FACT-Br -- SF-36 -- Unidimensional PROMs -- Symptom burden and interference -- MDASI-BT -- ESAS -- BFI -- Mood -- Distress thermometer -- POMS -- HADS -- PROMIS anxiety and depression -- BDI and BAI -- STAI -- Cognitive function -- Neuro-QoL -- MOS-COG-R -- FACT-Cog -- Sleep -- PSQI -- ISI -- ESS -- PROMIS SD and SRI -- Physical function and performance status -- PROMIS physical function -- Barthel Index -- Preliminary EORTC IADL-BN -- Financial toxicity -- COST-FACIT -- Applications of PROMs in neuro-oncology -- Personalized care and shared decision-making -- Treatment selection and evaluation -- Long-term monitoring and survivorship care -- Supportive and palliative care -- Prognostication -- Research and comparative effectiveness -- Population health and policy.
Modern approaches to capture PROs in neuro-oncology -- Electronic patient-reported outcome (ePRO) platforms -- Wearable devices and sensors -- Telehealth and remote monitoring -- Integration with electronic health records (EHRs) -- Future directions for PROs in neuro-oncology -- Personalized patient care -- Longitudinal monitoring -- Shared decision-making -- Research and clinical trials -- Integration with electronic health records (EHRs) -- Harnessing artificial intelligence (AI) -- Conclusion -- References -- Section II: Effects of neuro-oncology and systemic treatment on cognitive functioning -- Chapter 7: Imaging in neuro-oncology -- Introduction -- Gliomas -- Adult-type diffuse gliomas -- Astrocytoma, IDH-mutant -- Oligodendroglioma, IDH-mutant and 1p/19q co-deleted -- Glioblastoma, IDH-wild type -- Pediatric-type diffuse low-grade gliomas -- Diffuse astrocytomas, MYB or MYBL1-altered -- Angiocentric glioma -- Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) -- Diffuse low-grade gliomas, MAPK pathway altered -- Pediatric-type diffuse high-grade gliomas -- Diffuse midline glioma, H3K27-altered -- Diffuse hemispheric glioma, H3 G34-mutant -- Diffuse pediatric type high-grade glioma, H3-wildtype, and IDH-wildtype -- Infant-type hemispheric glioma -- Circumscribed astrocytic gliomas -- Pilocytic astrocytoma -- High-grade astrocytomas with piloid features -- Pleomorphic xanthoastrocytoma -- Subependymal giant cell astrocytoma -- Chordoid glioma -- Astroblastoma, MN1-altered -- Neuronal and glioneuronal tumors -- Ganglioglioma -- Dysembryoplastic neuroepithelial tumor (DNET) -- Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) -- Dysplastic cerebellar gangliocytoma -- Multinodular and vacuolating neuronal tumor (MVNT) -- CNS lymphoma -- Extra-axial tumors -- Tumors of the meninges -- Tumors of the cranial nerves.
Intraventricular neoplasms -- Pineal region neoplasms -- Sellar and suprasellar neoplasms -- Metastatic disease -- References -- Chapter 8: Pathology and treatment of primary and metastatic brain tumors -- Pathology and treatment of primary brain tumors -- Pathology of primary brain tumors -- Surgical therapy of primary brain tumors -- Radiation therapy of primary brain tumors -- Chemotherapy of primary brain tumors -- Molecular or ``targeted´´ treatment -- Tumor-treating fields -- Pathology and treatment of metastatic brain tumors -- Pathology of metastatic brain tumors -- Surgical therapy of metastatic brain tumors -- Radiation therapy of metastatic brain tumors -- Chemotherapy of metastatic brain tumors -- References -- Chapter 9: Overview of systemic treatment and toxicity in cancer patients -- Introduction -- Primary central nervous system tumors -- Breast cancer -- Prostate cancer -- Lung cancer -- Colorectal cancer -- Cutaneous melanoma -- Non-Hodgkin lymphoma -- Leukemia -- Myeloma -- Summary -- References -- Chapter 10: Delirium and mental status changes in neuro-oncology -- Introduction -- Delirium due to brain lesion -- Delirium due to local treatment -- Postoperative delirium -- Radiotherapy -- Delirium due to medication -- Chemotherapy -- Seizure medication -- Corticosteroids -- Supportive care -- Delirium due to complications of disease or treatment -- Infections -- Seizures -- Metabolic/hormonal complications -- Management of delirium -- References -- Chapter 11: The neuropsychological impact of surgical intervention and utility of awake craniotomies -- Introduction -- Tools to define neurocognition in awake craniotomy patients -- Anatomical basis of cognitive function in disease states indicating awake craniotomies -- Awake brain mapping craniotomy -- Indications and contraindications -- Intraoperative assessment of cognition.
Anatomical basis of brain mapping -- Mapping technique -- Mapping outcomes -- References -- Chapter 12: Neuropsychological implications of radiotherapy -- Introduction -- Pathophysiology -- Neurocognitive and psychologic assessment and guidelines -- Risk factors for psychosocial disorders -- Radiation dosimetry and neuropsychological consequences -- Treatment -- Depression and anxiety -- Adjustment disorder (AD) -- Posttraumatic stress disorder (PTSD) -- Neurobehavioral impairment in pediatric brain tumor survivors -- Conclusion -- References -- Chapter 13: Neuropsychological manifestations of chemotherapy -- CRCI-Risk factors -- Natural aging -- Genetic predisposition -- Miscellaneous -- CRCI-Pathogenesis -- Immune dysregulation, inflammatory response, and cytokines release -- Altered hormonal homeostasis -- Blood-brain barrier permeability and CRCI risk -- Oxidative stress and DNA damage -- Neurovascular features of CRCI -- Neurostructural features of CRCI -- Neuroimaging features of CRCI -- Electrophysiologic features of CRCI -- Neuropathological features of CRCI -- Psychiatric features of CRCI -- Neuropsychological assessment of CRCI -- Cognitive domains at risk -- Neuropsychological testing considerations -- Socioeconomic toxicity of cancer and cancer therapy -- CRCI-Treatment and prevention -- Future directions -- References -- Chapter 14: Neuropsychological issues related to immunotherapy -- Introduction -- Epidemiology and pathophysiology -- CNS immune-related adverse events from immune checkpoint inhibitors -- CNS immune-mediated events from CAR T-cells -- Encephalitis -- Aseptic meningitis -- Hypophysitis -- Other ICI-associated CNS immune-related adverse events -- CAR T-cell-mediated neurotoxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS) -- Conclusion -- References.
edited by Herbert B. Newton, Ashlee R. Loughan.